Empagliflozin for renal protection
Metadata[+] Show full item record
The use of empagliflozin appears to decrease the risk of microvascular renal progression, but whether this effect is from the medication or tighter glucose control is unclear, as the original trial did show a statistically lower HbA1C in the empagliflozin group.
Evidence-based practice 20, no. 8 (2017):E12